Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regeneron Pharmaceuticals
Biotech
Regeneron ends eye disease trial following safety review
The Titan study tested REGN7041, an anti-CD3 monoclonal antibody, in patients with inflammation of the uvea, the eye’s middle layer.
Darren Incorvaia
Aug 17, 2026 2:30pm
Regeneron backs $75M series A for antibody upstart Infinimmune
Aug 11, 2026 8:00am
BIO 2026: How a gut feeling transformed cancer treatment forever
Jun 25, 2026 9:23am
Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact
Jun 3, 2026 9:48am
Regeneron pens $2.3B Parabilis pact to develop new twist on ADCs
May 18, 2026 9:08am
Regeneron rocked by failure as melonama drug can't beat Keytruda
May 18, 2026 4:40am
